Besario, Nurman A.
HRN: 26-64-17 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
02/06/2025
CO-AMOXICLAV 625MG (TAB)
02/06/2025
02/13/2025
PO
625 Mg/tab
Q12
Wound And Abrasions
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes